EICHOR
● Completed
A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight
Condition: Healthy · Obese · Overweight · Sponsor: Eli Lilly and Company
About this study
The main purpose of this study is to see how much of orforglipron (study drug) gets into the bloodstream and how long it takes the body to get rid of it when given as capsules compared to tablets in healthy overweight and obese participants. The safety and tolerability (side effects) of orforglipron when given as capsules and tablets will also be evaluated. The study will be conducted in two parts, with part A and B lasting up to approximately 25 and 22 weeks each respectively, including the screening period.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (7)
| Anaheim Clinical Trials, LLC | Anaheim, California, United States | — |
| Collaborative Neuroscience Research, LLC | Los Alamitos, California, United States | — |
| Fortrea Clinical Research Unit | Daytona Beach, Florida, United States | — |
| Altasciences Company Inc. | Overland Park, Kansas, United States | — |
| QPS | Springfield, Missouri, United States | — |
| Fortrea Clinical Research Unit | Dallas, Texas, United States | — |
| Fortrea Clinical Research Unit | Madison, Wisconsin, United States | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06440980